Company Overview and News
Wins German cluster of the Pan-European JIVE initiative, will supply fuel cell modules for 40 buses to Belgian manufacturer Van Hool.
Criticism was recently raised of Tesla’s shares due to expectations for a vehicle delivery miss this quarter.
12-month backlog down 15% quarter-over-quarter, raising concerns about FY2018 revenues living up to lofty consensus expectations.
Q4 results largely in line with preliminary numbers released in conjunction with the company's business update in February.
Based on management's statements on the conference call, current consensus expectations for H1/2018 are too high.
China revenues expected to decline in FY2018 due to being largely limited to the minimum commitments under the take-or-pay MEA supply agreement with the company's Chinese joint venture.
500 commercial trucks are to be equipped with stacks manufactured by the company's Chinese joint venture.
A recent negative article about Ballard Power (BLDP) unjustly cast a dark shadow over the entire China fuel cell opportunity.
I have covered Plug Power (NASDAQ:PLUG) previously, so investors should view this article as an update to my earlier publishings on the company.
Ballard’s stock rose +167% in 2017 largely on a capital infusion from China's Broad Ocean, improved financial performance, and hopes that its Chinese partnerships would expand profit potential.
Fuel cell adoption looks like being on an inflection point, with many segments in many areas experiencing increased, and sometimes accelerated, uptake.
ArcelorMittal (MT - Free Report) – the biggest steel producer on the planet – is having an impressive run of late, thanks to improving global steel market conditions and the company’s internal initiatives. The Luxembourg-based company has seen its shares shoot up roughly 34% so far this year. The stock is also up around 29% over the last six months. ArcelorMittal has also seen strong earnings estimate revision activity over the past month, suggesting analysts are becoming more bullish on the firm’s prospects in both the short and long term.
Yesterday, in a landmark 3-2 vote, the Federal Communications Commission (FCC) approved a sweeping rollback of rules that were stumbling blocks to consolidation in the media and entertainment industry. FCC’s new proposals will bring an end to several longstanding rules designed to limit the monopoly of local broadcasters.
On Nov 17, 2017, we issued an updated research report on medical device major, Medtronic plc (MDT - Free Report) . The stock carries a Zacks Rank #4 (Sell).
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...